<DOC>
	<DOCNO>NCT00190268</DOCNO>
	<brief_summary>Rational study : 3,4-diaminopyridine suspect improved fatigue associate patient 's multiple sclerosis . In order confirm hypothesis , randomize , control versus placebo , double blind study perform .</brief_summary>
	<brief_title>Efficacy 3,4-DAP Fatigue Associated With Multiple Sclerosis</brief_title>
	<detailed_description>We propose randomize controlled trial 3,4-diaminopyridine placebo . The main objective : improvement fatigue diminution EMIF-SEP score arm treatment placebo arm . The hypothesis test 3,4-DAP efficacy fatigue multiple sclerosis .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Age &gt; = 18 year = &lt; 60 year Patients multiple sclerosis clinically define MIFSSEP score &gt; 44 , without deficit sleep without depression . Patients without treatment 3,4DAP since 3 month EDSS score &lt; 6 ASAT/ALAT &gt; 2 x ULN MADRS &gt; = 20 Abnormality cardiac rhythm Pregnancy Asthma Evolutive affection Renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>fatigue</keyword>
	<keyword>3,4-diaminopyridine</keyword>
</DOC>